Online citations, reference lists, and bibliographies.
← Back to Search

[Botulinum Toxin In The Musculoskeletal System].

R. Placzek, K. Heck, P. Pennekamp
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Over the last 20 years, botulinum toxin has proven to be an effective agent in the orthopaedic treatment of musculoskeletal diseases. The author presents a detailed summary of the data on the use of botulinum toxin in different indications. New indications and dosages will be developed in the coming years. As some of the newer indications for botulinum toxin are off-label, its pharmacokinetics must be carefully considered and the indication must be strictly based on current study data. Physicians using this drug should attend special professional courses.
This paper references
10.1016/j.ejpn.2008.10.006
Safety of botulinum toxin type A in children younger than 2 years.
S. I. Pascual-Pascual (2009)
10.1111/j.1469-8749.2008.02045.x
Development of the Gross Motor Function Classification System for cerebral palsy
P. Rosenbaum (2008)
10.1016/S0968-0004(02)02177-1
Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.
K. Turton (2002)
10.1053/j.jfas.2010.01.001
The diagnosis and treatment of heel pain: a clinical practice guideline-revision 2010.
J. L. Thomas (2010)
10.1017/S0012162204001410
Efficacy of botulinum toxin A, serial casting, and combined treatment for spastic equinus: a retrospective analysis.
A. Glanzman (2004)
[Insertional tendinopathies of te elbow].
Richard Placzek (2006)
10.1017/S001216220700014X.x
Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy
K. Desloovere (2007)
10.2340/16501977-0491
Ultrasonographic guided botulinum toxin type A treatment for plantar fasciitis: an outcome-based investigation for treating pain and gait changes.
Y. Huang (2010)
10.1002/mds.22661
Muscle biopsy substantiates long‐term MRI alterations one year after a single dose of botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers
A. Schroeder (2009)
10.1007/s11916-011-0205-3
Effects of Treatment of Myofascial Trigger Points on the Pain of Fibromyalgia
M. Giamberardino (2011)
10.1097/01241398-199307000-00013
Management of Cerebral Palsy with Botulinum‐A Toxin: Preliminary Investigation
L. Koman (1993)
10.1016/S0966-6362(99)00054-5
Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.
H. Graham (2000)
10.2106/JBJS.D.01896
Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study.
M. Hayton (2005)
10.3390/toxins5010060
Off Label Use of Botulinum Toxin in Children under Two Years of Age: A Systematic Review
C. Druschel (2013)
10.1111/j.1468-1331.2010.03126.x
Botulinum toxin assessment, intervention and after‐care for lower limb spasticity in children with cerebral palsy: international consensus statement
S. Love (2010)
Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial.
S. Wong (2005)
A review of fibromyalgia.
D. Nampiaparampil (2004)
10.1111/j.1468-1331.2006.01648.x
The structure and mode of action of different botulinum toxins
J. O. Dolly (2006)
10.3349/ymj.2010.51.4.579
Short-Term Effects of Combined Serial Casting and Botulinum Toxin Injection for Spastic Equinus in Ambulatory Children with Cerebral Palsy
E. S. Park (2010)
10.3390/toxins2092258
Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy
R. Placzek (2010)
10.1185/03007990903028203
Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?
K. Wohlfarth (2009)
[Assessment of muscle pain and hyperalgesia. Experimental and clinical findings].
L. Arendt-Nielsen (2003)
10.1001/JAMA.288.11.1357
Prognosis for gross motor function in cerebral palsy: creation of motor development curves.
P. Rosenbaum (2002)
10.1007/S11916-003-0057-6
The pathogenesis of muscle pain
S. Mense (2003)
10.1212/WNL.53.8.1850
Historical aspects of botulinum toxin
F. Erbguth (1999)
Neurologische Rehabilitation von Kindern mit Hirnschädigung im ersten und zweiten Lebensjahr – das Berliner Modell
S Rickensdorf (2009)
The key-muscle concept: a long-term low-dose injection strategy for botulinum toxin A treatment in cerebral palsy.
R. Placzek (2012)
10.1213/ANE.0000000000000192
Botulinum Toxin Type A Injections for Cervical and Shoulder Girdle Myofascial Pain Using an Enriched Protocol Design
Andrea L. Nicol (2014)
10.1097/01.WNF.0000240951.18821.50
Neurophysiological Double-Blind Trial of a Botulinum Neurotoxin Type A Free of Complexing Proteins
K. Wohlfarth (2007)
10.7326/0003-4819-146-10-200705150-00006
Narrative Review: The Pathophysiology of Fibromyalgia
A. Abeles (2007)
10.1111/j.1469-8749.1994.tb11864.x
BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY
A. Cosgrove (1994)
Toronto clinic's new approach.
Poul Rosenbaum (1993)
10.1503/cmaj.090906
Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: a randomized controlled trial
R. Espandar (2010)
10.1016/J.BERH.2007.02.014
Myofascial pain syndromes and their evaluation.
R. Bennett (2007)
10.1016/j.jbiomech.2010.08.020
Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox).
R. Fortuna (2011)
10.1007/PL00004951
Botulinum A toxins: units versus units
K. Wohlfarth (1997)
10.1007/S00482-003-0286-Y
[Botulinum toxin A in orthopedic pain therapy].
R. Placzek (2004)
10.1111/j.1469-8749.2005.tb01215.x
Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy
J. Ackman (2005)
[Diagnosis and therapy of myofascial trigger points].
D. Simons (2003)
10.1016/j.pain.2006.05.001
Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study
H. Göbel (2006)
10.1002/mds.22336
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
10.1007/s00702-011-0719-1
Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay
D. Dressler (2011)
10.3390/toxins7051629
Best Clinical Practice in Botulinum Toxin Treatment for Children with Cerebral Palsy
W. Strobl (2015)
10.1177/0269215511426159
Randomized controlled study of the efficacy of the injection of botulinum toxin type A versus corticosteroids in chronic plantar fasciitis: results at one and six months
I. Díaz-Llopis (2012)
10.2106/JBJS.F.00401
Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study.
R. Placzek (2007)
10.1097/01241398-199405000-00005
Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.
L. Koman (1994)
10.1016/j.ejpn.2009.09.005
The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.
F. Heinen (2010)
10.1097/PHM.0b013e3181cf564d
Comparison Between Botulinum Toxin and Corticosteroid Injection in the Treatment of Acute and Subacute Tennis Elbow: A Prospective, Randomized, Double-Blind, Active Drug-Controlled Pilot Study
Y. Lin (2010)
Botulinum toxin injection of eye muscles to correct strabismus.
A. B. Scott (1981)
10.1016/j.pain.2011.03.036
Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study
M. Ernberg (2011)
10.1111/j.1526-4637.2011.01163.x
Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections?
R. Benecke (2011)
10.1007/s00132-009-1534-3
[Botulinum toxin A in children with infantile cerebral palsy: indications and treatment concepts].
Richard Placzek (2010)
10.1177/15648265040251S105
Assessment of gross motor development in the WHO Multicentre Growth Reference Study.
T. Wijnhoven (2004)
10.2106/00004623-200411000-00003
Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy.
R. Kay (2004)
10.1179/crn.2012.014
Myofascial Pain of the Jaw Muscles: Comparison of Short-Term Effectiveness of Botulinum Toxin Injections and Fascial Manipulation Technique
L. Guarda-Nardini (2012)
10.1017/S0012162203001403
Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment.
M. Bottos (2003)
10.1097/01.phm.0000176339.73591.d7
Treatment of Pain Attributed to Plantar Fasciitis with Botulinum Toxin A: A Short-Term, Randomized, Placebo-Controlled, Double-Blind Study
Mary S. Babcock (2005)
10.1016/j.fas.2014.03.003
Plantar fasciopathy: revisiting the risk factors.
P. Beeson (2014)
10.1302/0301-620X.92B8.23086
The effect of injections of botulinum toxin type A combined with casting on the equinus gait of children with cerebral palsy.
S. Hayek (2010)
10.1111/j.1468-1331.2006.01652.x
Safety and efficacy of botulinum toxin type A following long‐term use
M. Naumann (2006)
10.1016/J.EJPN.2006.08.006
European consensus table 2006 on botulinum toxin for children with cerebral palsy.
F. Heinen (2006)
10.1097/AJP.0b013e31823ae65a
Is Botulinum Toxin A Effective for the Treatment of Plantar Fasciitis?
Christian-Dominik Peterlein (2012)
10.1093/PTJ/80.9.873
Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity.
D. Russell (2000)
10.1016/J.TOXICON.2008.04.085
Safety of Botulinum toxin a in cerebral palsy
Graham K. Kerr (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar